Use of human pluripotent stem cells to study and treat retinopathies

• Published in: World journal of stem cells Vol. 7; no. 3; pp. 596 - 604
• Main Authors: Ben M'Barek, Karim, Regent, Florian, Monville, Christelle
• Format: Journal Article
• Language: English
• Published: United States Baishideng Publishing Group Inc 26.04.2015
• Subjects: Review; Disease modeling; Drug screening; Human pluripotent stem cells; Retinitis pigmentosa
• ISSN: 1948-0210; 1948-0210
• DOI: 10.4252/wjsc.v7.i3.596

Human cell types affected by retinal diseases (such as age-related macular degeneration or retinitis pimentosa) are limited in cell number and of reduced accessibility. As a consequence, their isolation for in vitro studies of disease mechanisms or for drug screening efforts is fastidious. Human pluripotent stem cells (hPSCs), either of embryonic origin or through reprogramming of adult somatic cells, represent a new promising way to generate models of human retinopathies, explore the physiopathological mechanisms and develop novel therapeutic strategies. Disease-specific human embryonic stem cells were the first source of material to be used to study certain disease states. The recent demonstration that human somatic cells, such as fibroblasts or blood cells, can be genetically converted to induce pluripotent stem cells together with the continuous improvement of methods to differentiate these cells into disease-affected cellular subtypes opens new perspectives to model and understand a large number of human pathologies, including retinopathies. This review focuses on the added value of hPSCs for the disease modeling of human retinopathies and the study of their molecular pathological mechanisms. We also discuss the recent use of these cells for establishing the validation studies for therapeutic intervention and for the screening of large compound libraries to identify candidate drugs.